Synopsis
Synopsis
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
FDF
0
FDA Orange Book
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. Bromoprid
2. Bromopride Dihydrochloride
3. Bromopride Hydrochloride
4. Viaben
1. 4093-35-0
2. Artomey
3. Valopride
4. Bromoprida
5. Viaben
6. Movipride
7. 4-amino-5-bromo-n-(2-(diethylamino)ethyl)-o-anisamide
8. 4-amino-5-bromo-n-[2-(diethylamino)ethyl]-2-methoxybenzamide
9. Val 13081
10. Nsc-758391
11. Emepride
12. 75473v2yzk
13. Bromopride (inn)
14. Ncgc00016646-02
15. Cas-4093-35-0
16. Bromopride [inn]
17. Benzamide, 4-amino-5-bromo-n-(2-(diethylamino)ethyl)-2-methoxy-
18. Benzamide, 4-amino-5-bromo-n-[2-(diethylamino)ethyl]-2-methoxy-
19. Dsstox_cid_25383
20. Dsstox_rid_80841
21. Dsstox_gsid_45383
22. Bromoprida [spanish]
23. O-anisamide, 4-amino-5-bromo-n-[2-(diethylamino)ethyl]-
24. Bromopridum
25. 4-amino-5-bromo-n-(2-(diethylamino)ethyl)-2-methoxybenzamide
26. Bromoprid
27. Emoril
28. Bromopride [inn:dcf]
29. O-anisamide, 4-amino-5-bromo-n-(2-(diethylamino)ethyl)-
30. Bromopridum [inn-latin]
31. Bromoprida [inn-spanish]
32. Sr-01000841242
33. Einecs 223-842-2
34. Brn 2381893
35. Unii-75473v2yzk
36. N-(diethylaminoethyl)-2-methoxy-4-amino-5-bromobenzamide
37. Bromopride-[d3]
38. Movipride (tn)
39. Prestwick_61
40. Spectrum_001394
41. Bromopride [mi]
42. Prestwick0_000704
43. Prestwick1_000704
44. Prestwick2_000704
45. Prestwick3_000704
46. Spectrum2_001527
47. Spectrum3_001559
48. Spectrum4_000726
49. Spectrum5_000970
50. Bromopride [mart.]
51. Bromopride [who-dd]
52. Schembl54497
53. Bspbio_000887
54. Bspbio_003038
55. Kbiogr_000992
56. Kbioss_001874
57. Mls002153965
58. Divk1c_000317
59. Spectrum1503108
60. Spbio_001314
61. Spbio_002808
62. Bpbio1_000977
63. Chembl399510
64. Dtxsid0045383
65. Chebi:95304
66. Hms500p19
67. Kbio1_000317
68. Kbio2_001874
69. Kbio2_004442
70. Kbio2_007010
71. Kbio3_002538
72. Ninds_000317
73. Hms1570m09
74. Hms1922e21
75. Hms2097m09
76. Hms2230k23
77. Hms3374m06
78. Hms3714m09
79. Pharmakon1600-01503108
80. Hy-b1164
81. Zinc2038104
82. Tox21_110543
83. Bdbm50247887
84. Ccg-39305
85. Nsc758391
86. Akos015994598
87. Tox21_110543_1
88. Cs-4764
89. Db09018
90. Hs-0004
91. Nsc 758391
92. Idi1_000317
93. Ncgc00016646-01
94. Ncgc00016646-05
95. Ncgc00095309-01
96. Smr001233304
97. Sbi-0051774.p002
98. Ab00052316
99. Ft-0663848
100. D07101
101. Ab00052316_08
102. A917874
103. Q1958189
104. Sr-01000841242-2
105. Sr-01000841242-3
106. Brd-k73642618-001-05-9
107. Brd-k73642618-001-08-3
108. 4-amino-5-bromo-n-[2-(diethylamino)ethyl]-2-methoxybenzamide #
| Molecular Weight | 344.25 g/mol |
|---|---|
| Molecular Formula | C14H22BrN3O2 |
| XLogP3 | 2.8 |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 4 |
| Rotatable Bond Count | 7 |
| Exact Mass | 343.08954 g/mol |
| Monoisotopic Mass | 343.08954 g/mol |
| Topological Polar Surface Area | 67.6 Ų |
| Heavy Atom Count | 20 |
| Formal Charge | 0 |
| Complexity | 300 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Bromopride in indicated in the treatment of nausea and vomiting, including PONV (post-operative nausea and vomiting), gastroesophageal reflux disease (GERD/GORD), as well as endoscopy preparation and radiographic studies of the GI tract.
Antiemetics
Drugs used to prevent NAUSEA or VOMITING. (See all compounds classified as Antiemetics.)
Dopamine Antagonists
Drugs that bind to but do not activate DOPAMINE RECEPTORS, thereby blocking the actions of dopamine or exogenous agonists. Many drugs used in the treatment of psychotic disorders (ANTIPSYCHOTIC AGENTS) are dopamine antagonists, although their therapeutic effects may be due to long-term adjustments of the brain rather than to the acute effects of blocking dopamine receptors. Dopamine antagonists have been used for several other clinical purposes including as ANTIEMETICS, in the treatment of Tourette syndrome, and for hiccup. Dopamine receptor blockade is associated with NEUROLEPTIC MALIGNANT SYNDROME. (See all compounds classified as Dopamine Antagonists.)
A - Alimentary tract and metabolism
A03 - Drugs for functional gastrointestinal disorders
A03F - Propulsives
A03FA - Propulsives
A03FA04 - Bromopride
Clearance
Renal, 10-14% as original compound.
Hepatic.
INTERMEDIATES SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
NEWS #PharmaBuzz
Global Sales Information
Market Place
ABOUT THIS PAGE
A Bromopride manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Bromopride, including repackagers and relabelers. The FDA regulates Bromopride manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Bromopride API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Bromopride manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Bromopride supplier is an individual or a company that provides Bromopride active pharmaceutical ingredient (API) or Bromopride finished formulations upon request. The Bromopride suppliers may include Bromopride API manufacturers, exporters, distributors and traders.
click here to find a list of Bromopride suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
Bromopride Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Bromopride GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Bromopride GMP manufacturer or Bromopride GMP API supplier for your needs.
A Bromopride CoA (Certificate of Analysis) is a formal document that attests to Bromopride's compliance with Bromopride specifications and serves as a tool for batch-level quality control.
Bromopride CoA mostly includes findings from lab analyses of a specific batch. For each Bromopride CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Bromopride may be tested according to a variety of international standards, such as European Pharmacopoeia (Bromopride EP), Bromopride JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Bromopride USP).
LOOKING FOR A SUPPLIER?
